Dr Reddy’s Laboratories Q2 results FY25 disclosed a 9% year-on-year decrease in the consolidated profit after tax. On the Dr Reddy’s Laboratories Q2 results date which was November 5, 2024, the Dr Reddy Lab share price closed at ₹1,272.20. On November 6, 2024, Dr Reddy Lab share price opened at ₹1,274.
Dr Reddy’s Laboratories Q2 Results FY25: Key Highlights
- Dr Reddy’s Laboratories Q2 results pointed out that the consolidated net profit was ₹13,415 million in FY25 lower than the net profit of ₹14,800 million in Q2 FY24.
- The revenues were at ₹80,162 million, up 17% YoY from ₹68,802 million in Q2 FY24.
- EBITDA rose to ₹22,803 million which is 28.4% of the revenues according to Dr Reddy Lab results.
- SG&A Expenses were at ₹23,007 million, up 22% YoY while R&D Expenses were at ₹7,271 million, up 33% YoY in the second quarter of the financial year 2024-25.
- Dr Reddy Lab share price has delivered positive returns of 2.36% in the last 1 day as on November 6, 2024.
Dr Reddy’s Laboratories Q2 Results FY25: Segment Performance
- Global Generics: This segment earned a revenue of ₹71,576 million, up 17% YoY in the Q2 FY25. North America business revenue grew by 17% to ₹37,281 million, Europe grew by 9% to ₹5,770 million and India rose by 18% to ₹13,971 million in the second quarter.
- Pharmaceutical Services and Active Ingredients (PSAI): As per Dr Reddy’s Laboratories Q2 results, this segment’s revenue was at ₹8,407 million, up 20% YoY.
Dr Reddy’s Laboratories Q2 Results: Business Highlights
- Dr Reddy Lab results mentioned that the pharma player has completed the acquisition of the Nicotine Replacement Therapy (NRT) portfolio at GBP 458 million.
- The company started the operations of Dr. Reddy’s and Nestle Health Science Limited in August 2024.
- Dr Reddy Lab got marketing authorization from the European Commission for the rituximab biosimilar.
- The company received approval from the USFDA for an Investigational New Drug (IND) application used for the treatment of lymphoid malignancies.
- Dr Reddy Laboratories entered into a patent licensing agreement with Takeda to commercialize Vonoprazan (novel gastro-intestinal drug) in India.
Dr Reddy Lab Results: Management Commentary
G V Prasad, Co-Chairman & MD of Dr Reddy’s Laboratories said that – “We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestlé and completed the acquisition of Nicotinell and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation.”
About Dr Reddy’s Laboratories
Dr Reddy’s Laboratories, incorporated in 1984, is a global pharma company based in Hyderabad, India. The company product and services basket includes the APIs, generics, biosimilars, and OTC. Its footprint spans across the US, India, Russia, and China markets. Highlighting Dr Reddy Lab share price performance, it has generated a positive return of 4.18% in the last 1 week (as on November 6, 2024).
Keep exploring stocks and open demat account with SMC Global Securities. Stay tuned for the upcoming Nifty 50 companies quarterly results.
Reference
https://www.drreddys.com/cms/cms/sites/default/files/2024-11/Q2%20FY25%20Results%20.pdf
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
